Brokerages Anticipate Merck & Co., Inc. (NYSE:MRK) to Announce $1.39 EPS

Equities analysts predict that Merck & Co., Inc. (NYSE:MRK) will announce earnings per share (EPS) of $1.39 for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Merck & Co., Inc.’s earnings, with the highest EPS estimate coming in at $1.44 and the lowest estimate coming in at $1.37. Merck & Co., Inc. posted earnings of $1.30 per share in the same quarter last year, which suggests a positive year-over-year growth rate of 6.9%. The company is expected to report its next earnings report before the market opens on Friday, July 31st.

According to Zacks, analysts expect that Merck & Co., Inc. will report full-year earnings of $5.31 per share for the current financial year, with EPS estimates ranging from $5.17 to $5.40. For the next fiscal year, analysts forecast that the firm will report earnings of $5.76 per share, with EPS estimates ranging from $4.52 to $6.39. Zacks’ earnings per share averages are a mean average based on a survey of research analysts that cover Merck & Co., Inc..

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, April 28th. The company reported $1.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.16. Merck & Co., Inc. had a return on equity of 52.46% and a net margin of 21.10%. The business had revenue of $12.06 billion during the quarter, compared to analyst estimates of $11.46 billion. During the same period last year, the company earned $1.22 EPS. The company’s revenue for the quarter was up 11.5% on a year-over-year basis.

MRK has been the topic of several research analyst reports. Credit Suisse Group restated a “buy” rating and set a $95.00 target price on shares of Merck & Co., Inc. in a research note on Monday, May 4th. Mizuho reiterated a “buy” rating and set a $100.00 price objective on shares of Merck & Co., Inc. in a research note on Tuesday, June 23rd. ValuEngine lowered Merck & Co., Inc. from a “hold” rating to a “sell” rating in a research report on Monday, June 8th. SVB Leerink decreased their price target on Merck & Co., Inc. from $98.00 to $95.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 29th. Finally, Barclays decreased their price target on Merck & Co., Inc. from $93.00 to $90.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 29th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eleven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $94.15.

In other Merck & Co., Inc. news, Director Wendell P. Weeks sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $76.02, for a total value of $380,100.00. Following the sale, the director now owns 5,100 shares in the company, valued at $387,702. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.28% of the stock is currently owned by company insiders.

Large investors have recently modified their holdings of the stock. Sowa Financial Group Inc. bought a new stake in Merck & Co., Inc. during the fourth quarter worth approximately $27,000. Total Clarity Wealth Management Inc. acquired a new position in Merck & Co., Inc. in the 4th quarter worth approximately $27,000. Stephenson National Bank & Trust acquired a new position in Merck & Co., Inc. in the 4th quarter worth approximately $28,000. CBIZ Investment Advisory Services LLC boosted its stake in Merck & Co., Inc. by 180.7% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the company’s stock worth $32,000 after purchasing an additional 271 shares during the period. Finally, Lion Street Advisors LLC acquired a new position in Merck & Co., Inc. in the 1st quarter worth approximately $35,000. Hedge funds and other institutional investors own 74.33% of the company’s stock.

NYSE MRK traded up $1.21 on Tuesday, reaching $77.33. 9,483,833 shares of the stock traded hands, compared to its average volume of 12,357,683. The company has a debt-to-equity ratio of 0.82, a quick ratio of 0.87 and a current ratio of 1.11. The company has a fifty day moving average price of $78.27 and a 200-day moving average price of $81.87. The company has a market cap of $189.79 billion, a price-to-earnings ratio of 19.58, a PEG ratio of 2.10 and a beta of 0.50. Merck & Co., Inc. has a 12 month low of $65.25 and a 12 month high of $92.64.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, July 7th. Shareholders of record on Monday, June 15th will be paid a $0.61 dividend. The ex-dividend date is Friday, June 12th. This represents a $2.44 annualized dividend and a dividend yield of 3.16%. Merck & Co., Inc.’s payout ratio is currently 47.01%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

See Also: What is Call Option Volume?

Get a free copy of the Zacks research report on Merck & Co., Inc. (MRK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.